Loading
Adding PCV chemotherapy after radiotherapy for grade 2 glioma in adults who were over 40 or had residual tumour lengthened median survival from about eight to over thirteen years, one of the largest gains ever seen in neuro-oncology.
Phase 3 trial of 251 patients with grade 2 astrocytoma, oligodendroglioma or oligoastrocytoma who were either aged 40 or over or had undergone subtotal resection, randomised to radiotherapy alone or radiotherapy followed by six cycles of procarbazine, lomustine and vincristine (PCV).
Median overall survival was 13.3 years with PCV against 7.8 years with radiotherapy alone (hazard ratio 0.59), with benefit across histologies in later molecular analyses, strongest in IDH-mutant tumours.
Radiotherapy followed by PCV is the standard for high-risk grade 2 IDH-mutant glioma; whether temozolomide can replace PCV, and whether vorasidenib can defer both, are the current questions.
Shares Procarbazine, Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, Vincristine.
Shares Procarbazine, Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, Vincristine.
Shares Procarbazine, Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, Vincristine.
Shares Procarbazine, Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, Vincristine.
Shares Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, Astrocytoma, IDH-mutant (grades 2 to 4).
Shares Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, Astrocytoma, IDH-mutant (grades 2 to 4).
Shares Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, Astrocytoma, IDH-mutant (grades 2 to 4), New England Journal of Medicine.
Shares Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, Astrocytoma, IDH-mutant (grades 2 to 4).